Biogen's "growth products" — about a half-dozen products including Leqembi — contributed $800 million to the firm's $2.28 ...

GT Bio's CEO Michael Breen said he's seen "encouraging trends" in ongoing AML Phase I trials that could validate the platform's efficacy as the company moves into solid tumors. The firm's leadership ...

Long-term data on four patients' who had received avigbagene parvec gave the firm confidence to advance a late-stage single-arm trial that can support regulatory approval.

Dementia care isn't just about new drugs, said the author of a cost-effectiveness study comparing collaborative care, Leqembi ...

"All healthcare providers should be aware of the risks of DPD deficiency," inform patients of toxicity risks, and test patients unless treatment is immediately needed, the agency said.

Despite another quarter of declining sales for Ibrance, its top-selling oncology drug, revenue for Pfizer's overall oncology ...

The firm is hoping to make up for revenue lost to generic competition in coming years by growing adoption of treatments like ...

This year, the firm will focus on commercializing and further developing the ovarian cancer drug and discuss the registrational path with the FDA for a KRAS G12D inhibitor.

The firm provided updates alongside Q4 and full-year 2025 financial results, and reported $19.29 billion and $65.18 billion ...

The company has garnered FDA fast-track status and will soon start a controlled trial of its oncolytic virus with standard therapy.

Wave is expecting feedback from US regulators on a path forward for WVE-006 as a potential alpha-1 antitrypsin deficiency therapy in mid-2026.

Lilly will license programmable recombinases developed by Seamless to create new gene-editing therapies that could treat ...